DECLARATION

I declare that this dissertation is my own work. It is being submitted for the Masters degree in Internal Medicine at the University of Zambia, Lusaka. It has not been submitted before for any degree or examination at this or any other University.

Signed	
- -	Dr. Mujajati Aaron D
Signed	
	Supervisor: Dr S. Lakhi (Head of Department Internal Medicine)
Signed	
C	Co-supervisor: Dr A. Mweemba (Consultant Nephrologist)
Signed	
o. _B .104	Co-supervisor: Dr P. Mwaba (Consultant Physician)

A.Mujajati

COPYRIGHT

Dr. Mujajati Aaron D

2013

All rights reserved: no part of this dissertation may be produced, stored in a retrievable system or transmitted in any form or by any means (electronic or otherwise) without prior consent of the author.

©2013 by Mujajati Aaron D. All rights reserved

A.Mujajati

APPROVAL

This dissertation of **Dr. Mujajati Aaron D** is approved as fulfilling the requirement for the award of the degree of **Master of Medicine in Internal Medicine** by the University of Zambia.

Head of Department:
Name: Dr. S. Lakhi
Signature:

Date:....

A.Mujajati

DEDICATION

To Science

ACKNOWLEDGEMENTS

The execution and successful completion of this study would not have been possible without the contribution of the following people;

My supervisors: Dr S. Lakhi, Dr A. Mweemba, and Dr P. Mwba for being constant guides throughout this project;

Dr. Musonda Patrick for helping formulate the research protocol;

Dr B. Andrews and Dr. Omar Siddiqi for the invaluable technical support. I am truly thankful;

Dr L. Mulenga and the staff at the CIDRZ Kalingalinga laboratory.

My research assistants for being dedicated to this research and seeing it through to its completion;

The health workers working in the general medical wards at University Teaching Hospital;

My wife Dr. Patel Ushmaben and my children Keya and Aeisha for being great pillars of support;

Finally, I would like to thank the participants of this study and their caregivers without whose participation this research would not have been possible.

A.Mujajati

ABSTRACT

Background

Amphotericin-B deoxycholate is an essential agent in the management of cryptococcal

meningitis. Despite its proven antifungal potency it has several untoward side effects

which include renal failure, hypomagnesaemia, hypokalaemia, phlebitis and nephrogenic

diabetes insipidus. Hypomagnesaemia is an important but under diagnosed electrolyte

abnormality in patients on Amphotericin-B therapy. The effects of hypomagnesaemia on

mortality and morbidity in critically ill patients are well documented.

In clinical practice, when patients are receiving Amphotericin-B for treatment of

cryptococcal meningitis, routine monitoring of serum potassium and creatinine are

advocated for but with little to no emphasis on magnesium. Therefore, this study was

carried out on HIV infected patients with cryptococcal meningitis, who were treated with

amphotericin-B at the University Teaching Hospital in order to determine the incidence

of hypomagnesaemia if any.

Methods

Design: Observational Cohort study.

Setting: University Teaching Hospital (UTH), Lusaka, Zambia.

Data Collection and Analysis: 54 HIV infected patients with cryptococcal meningitis and

scheduled to receive Amphotericin-B therapy were enrolled and each was followed up

prospectively for 14 days. Baseline and follow-up (day 14) data which included socio-

demographic characteristics, drug history, co-morbidities vital signs, Glasgow Coma

Score (GCS), Karnofsky Score, serum creatinine, urea, magnesium, potassium, sodium

and haemoglobin were collected. Statistical software STATA version 12.0 was used to

analyse the data. The incidence of hypomagnesaemia was calculated using Binomial

exact methods. A conditional logistic regression was used to estimate the unadjusted and

adjusted odds ratio of hypomagnesaemia for various variables.

νi

A.Mujajati

Results

We recruited fifty-four participants out of which thirty-three (n=33) were male and twenty-one (n=21) were female. The baseline prevalence of hypomagnesaemia was 40.7% and 96.8% after 14 days of *Amphotericin-B* therapy. CD4 count, NSAID use and rise in creatinine were associated with hypomagnesaemia. However, there was no significant association with alcohol, chronic diarrhea, HAART use and anaemia. The incidence of hypomagnesaemia after 14 days of Amphotericin-B therapy was 97 per 100 person days (95 % CI: 84, 99). We did not find correlation between serum magnesium and potassium ($R^2 = 0.025$). All-cause mortality was 25% but the odds of death in those who were hypomagnesaemic were low OR=0.95 (95% CI: 0.93, 0.96).

Conclusion

The baseline prevalence and Incidence of hypomagnesaemia after 14 days of *Amphotericin-B therapy* were high. Therefore, routine magnesium testing, monitoring and supplementation should be considered in HIV infected patients who are treated with Amphotericin-B. The study was inconclusive on the use of potassium levels as a surrogate marker for hypomagnesaemia because there was no correlation between serum magnesium and potassium.

LIST OF TABLES, FIGURES AND GRAPHS

Figure 1	Study Process	Page 14
Figure 2	Correlation of Magnesium to Potassium	Page 23
Table 1	Definitions	Page 15
Table 2	Baseline characteristics of study population	Page 17
Table 3	Baseline and follow-up results for all participants	Page 18
Table 4	Baseline and Follow-up results for completion of Treatment	Page 19
Table 5	Baseline Characteristics of Hypomagnesaemia	Page 20
Table 6	Baseline and Follow-up measurements	Page 21
Table 7	Unadjusted and Adjusted Odds ratios	Page 22

LIST OF ABBREVIATIONS

ART - Anti Retroviral Therapy

AIDS - Acquired Immune deficiency syndrome

Ampho-B - Amphotericin-B

BMI - Body Mass Index

CSF - Cerebral Spinal Fluid

CD4 - Cluster of Differentiation number 4 T-Cell Lymphocytes

CM - Cryptococcal Meningitis

Cr - Creatinine

GCS - Glasgow Coma Score

HAART - Highly Active Antiretroviral Therapy

HIV - Human Immunodeficiency Virus

K - Potassium

K Score - Karnofsky Score

Mg - Magnesium

Na - Sodium

NSAIDS - Non-steroidal Anti-inflammatory Drugs

PID - Patient Identification Number

TB - Tuberculosis

UTH - University Teaching Hospital

References

TABLE OF CONTENTS

CHAPTER 1	
Introduction	page 1
CHAPTER 2	
Literature review	page 3
CHAPTER 3	
Statement of the problem	page 8
Study justification	page 8
Hypothesis	page 8
Research Question	page 8
Objectives	page 9
CHAPTER 4	
Methods	page 10
Analysis	page 15
CHAPTER 5	
Results	page 17
CHAPTER 6	
Discussion	page 24
Study limitations	page 27
CHAPTER 7	
Conclusion	
Recommendations	

page 29

A.Mujajati

APPENDICES

Data collection sheet	Appendix 1
Consent form	Appendix 2
Karnofsky Score	Appendix 3
Glasgow Coma	Appendix 4
Research Ethics Approval	Appendix 5